Biogen (BIIB) tops Q2 expectations, raises profit guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Biogen (BIIB) PT Raised to $292 at RBC Capital
August 2, 2024 6:24 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Biogen (NASDAQ: BIIB) to $292.00 (from $282.00) while maintaining a Outperform rating.
The analyst comments "BIIB's 2Q was better than today's stock action might suggest; while the beat was in partially driven by a few... More
Biogen (BIIB) Tops Q2 EPS by 127c; profit guidance raised
August 1, 2024 6:59 AM EDTBiogen (NASDAQ: BIIB) reported Q2 EPS of $5.28, $1.27 better than the analyst estimate of $4.01. Revenue for the quarter came in at $2.47 billion versus the consensus estimate of $2.39 billion.
GUIDANCE:
Biogen sees FY2024 EPS of $15.75-$16.25, versus the consensus of $15.58.... More
Biogen lifts profit forecast, signals progress in turnaround effort
August 1, 2024 6:50 AM EDTBy Manas Mishra and Mariam Sunny
(Reuters) -Biogen lifted its full-year profit forecast on Thursday due to cost cuts and better-than-expected sales of its various treatments, even as the U.S. adoption of its Alzheimer's drug remains slow.
CEO Christopher Viehbacher, who is spearheading a turnaround at Biogen since taking over the top job in 2022, said the company was now positioned for growth after a series of cost-cutting efforts, multiple acquisitions and a... More
Biogen (BIIB) Reports New Data Showing Three Years of Continuous Treatment with Dual-Acting LEQEMBI Continues to Significantly Benefit Early Alzheimer's Disease Patients
July 30, 2024 5:00 PM EDTEisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (A) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, USA, and virtually. Dual-acting lecanemab is the only early AD treatment widely available to support neuronal function by clearing the highly toxic... More
